About this Research Topic
Ubiquitylation is a post-translational protein modification that is associated with protein homeostasis and function. The covalent attachment of a highly conserved 76-amino acid polypeptide ubiquitin at a lysine residue of substrates is coordinated by the E1-E3-ubiquitin ligases. In the presence of ATP, ubiquitin activated by E1 is delivered to E2, and E3 finally transfers ubiquitin to its substrates, leading to proteasomal degradation, signal transduction and cellular processes including DNA repair and protein trafficking. The fate of ubiquitylated proteins is dependent on the ubiquitin-conjugated sites and/or the number of ubiquitin (mono- or poly-ubiquitylation). Recent studies demonstrate that the bone and immune system required for maintenance of homeostasis is controlled through regulation of protein ubiquitylation.
The aim of this Research Topic is to clarify the molecular mechanisms by which bone and immune system is regulated through protein ubiquitylation. We would like to gain a great understanding on the roles of ubiquitylated proteins in the pathogenesis of autoimmune diseases such as rheumatic diseases and inflammatory bowel diseases that are developed by abnormal bone and immune system. To date, small-molecule inhibitors targeting the proteasome or the E1-E3 ligases have been developed, and the proteasome inhibitor bortezomib has a clinical indication for multiple myeloma and lymphoproliferative disorders. We are confident that this Research Topic will provide evidence that targeting protein ubiquitylation may be a novel therapeutic strategy for autoimmune disorders and be of strong interest to the diverse scientific readers of Frontiers in Immunology.
We welcome the submission of Review, Original Research, Perspective, Clinical Trial and Case Report articles covering, but not limited to, the following sub-topics:
1. The roles of protein ubiquitylation for differentiation and function of bone associated cells including osteoblasts and osteoclasts as well as immune cells including lymphocytes, monocytes/macrophages and granulocytes
2. Advanced imaging of bone and immune cell locomotion and recruitment through protein ubiquitylation
3. The roles of protein ubiquitylation for the pathogenesis of autoimmune diseases
4. The therapeutic potential of small-molecule inhibitors of protein ubiquitylation for autoimmune diseases
The aim of this Research Topic is to clarify the molecular mechanisms by which bone and immune system is regulated through protein ubiquitylation. We would like to gain a great understanding on the roles of ubiquitylated proteins in the pathogenesis of autoimmune diseases such as rheumatic diseases and inflammatory bowel diseases that are developed by abnormal bone and immune system. To date, small-molecule inhibitors targeting the proteasome or the E1-E3 ligases have been developed, and the proteasome inhibitor bortezomib has a clinical indication for multiple myeloma and lymphoproliferative disorders. We are confident that this Research Topic will provide evidence that targeting protein ubiquitylation may be a novel therapeutic strategy for autoimmune disorders and be of strong interest to the diverse scientific readers of Frontiers in Immunology.
We welcome the submission of Review, Original Research, Perspective, Clinical Trial and Case Report articles covering, but not limited to, the following sub-topics:
1. The roles of protein ubiquitylation for differentiation and function of bone associated cells including osteoblasts and osteoclasts as well as immune cells including lymphocytes, monocytes/macrophages and granulocytes
2. Advanced imaging of bone and immune cell locomotion and recruitment through protein ubiquitylation
3. The roles of protein ubiquitylation for the pathogenesis of autoimmune diseases
4. The therapeutic potential of small-molecule inhibitors of protein ubiquitylation for autoimmune diseases
Keywords: E3-ubiquitin ligase, bone, immunology, osteoimmunology, ubiquitylation, macrophage, lymphocyte
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
